Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs categorized into 13 functional groups have been formally approved for the treatment of the following 9 human infectious diseases: (i) HIV infections (protease inhibitors, integrase inhibitors, entry inhibitors, nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and acyclic nucleoside phosphonate analogues), (ii) hepatitis B virus (HBV) infections (lamivudine, interferons, nucleoside analogues, and acyclic nucleoside phosphonate analogues), (iii) hepatitis C virus (HCV) infections (ribavirin, interferons, NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors), (iv) herpesvirus infections (5-substituted 2'-deoxyuridine analogues, entry inhibitors, nucleoside analogues, pyrophosphate analogues, and acyclic guanosine analogues), (v) influenza virus infections (ribavirin, matrix 2 protein inhibitors, RNA polymerase inhibitors, and neuraminidase inhibitors), (vi) human cytomegalovirus infections (acyclic guanosine analogues, acyclic nucleoside phosphonate analogues, pyrophosphate analogues, and oligonucleotides), (vii) varicella-zoster virus infections (acyclic guanosine analogues, nucleoside analogues, 5-substituted 2'-deoxyuridine analogues, and antibodies), (viii) respiratory syncytial virus infections (ribavirin and antibodies), and (ix) external anogenital warts caused by human papillomavirus infections (imiquimod, sinecatechins, and podofilox). Here, we present for the first time a comprehensive overview of antiviral drugs approved over the past 50 years, shedding light on the development of effective antiviral treatments against current and emerging infectious diseases worldwide.

中文翻译：

---

过去50年中批准的抗病毒药物。

和（无环鸟苷类似物），（v）流感病毒感染（利巴韦林，基质2蛋白抑制剂，RNA聚合酶抑制剂和神经氨酸酶抑制剂），（vi）人巨细胞病毒感染（无环鸟苷类似物，无环核苷膦酸酯类似物，焦磷酸盐类似物和寡核苷酸），（vii）水痘带状疱疹病毒感染（无环鸟苷类似物，核苷类似物，5-取代的2'-脱氧尿苷类似物和抗体），（viii）呼吸道合胞病毒感染（利巴韦林和抗体），以及（ix）外生殖器由人乳头瘤病毒感染（咪喹莫特，sinecatechins和podofilox）引起的疣。在这里，我们将首次全面介绍过去50年来获批的抗病毒药物，